S0916, MLN1202 in Treating Patients With Bone Metastases

DISEASE CHARACTERISTICS: * Radiographically documented metastases to the bone by bone scan, x-ray, CT scan, MRI, or PET scan within the past 42 days * Documentation of progression of metastatic disease by serial scans is not required for study entry * No untreated or progressive brain metastases * History of brain metastases allowed provided they have been treated and remain controlled PATIENT CHARACTERISTICS: * Zubrod performance status 0-2 * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Must consent to urine and blood specimen submissions * No concurrent uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with the study requirements * No known hypersensitivity to anti-CCR2 monoclonal antibody MLN1202 or other recombinant human antibodies PRIOR CONCURRENT THERAPY: * At least 14 days since prior radiotherapy and recovered (≤ grade 1 from all related toxicities) * At least 84 days since prior radionuclide therapy (e.g., strontium, samarium) and recovered (≤ grade 1 from all related toxicities) * More than 14 days since prior investigational agents, chemotherapeutic agents, or other anticancer agents * Concurrent bisphosphonate therapy for bone metastases allowed provided treatment was initiated ≥ 28 days before study entry * No initiation of bisphosphonates during study treatment * Concurrent hormonal therapy (e.g., anti-estrogens or anti-androgens) or stable doses of steroids for cancer allowed provided treatment was initiated \> 14 days before study entry * No concurrent G-CSF or other growth factor support